A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

BACKGROUND: Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yuexian, Zong, Huifang, Han, Lei, Xie, Yueqing, Jiang, Hua, Gilly, John, Zhang, Baohong, Lu, Huili, Chen, Jie, Sun, Rui, Pan, Zhidi, Zhu, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216678/
https://www.ncbi.nlm.nih.gov/pubmed/32398042
http://dx.doi.org/10.1186/s13046-020-01564-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216678/
https://www.ncbi.nlm.nih.gov/pubmed/32398042
http://dx.doi.org/10.1186/s13046-020-01564-4

Ejemplares similares